Gabapentin Capsule
Product Images NDC 50090-0949

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 50090-0949). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula (Gabapentin Fig1)

This image shows a formula for calculating creatinine clearance (CLCr) based on age, weight, gender, and serum creatinine levels. It provides a mathematical expression useful for clinical assessment, with adjustments for female patients.*

FDA Label Image

Figure 1 (Gabapentin Fig2)

A line graph displaying mean pain scores over an 8-week period comparing placebo and Gabapentin at 3600 mg/day. The x-axis shows weeks labeled from Baseline to Week 8, divided into a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 9. Gabapentin's line trends downwards, indicating reduced pain scores, while placebo remains relatively constant.*

FDA Label Image

Figure 2 (Gabapentin Fig3)

A line graph depicting mean pain score over a 7-week period comparing placebo and two dosages of gabapentin (1800 mg/day and 2400 mg/day). The x-axis represents weeks from baseline through week 7, and the y-axis shows mean pain scores from 0 to 10. The graph includes a 3-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Figure 3 (Gabapentin Fig4)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and Gabapentin (GBP) at various doses. Study 1 shows 12% responders for placebo and 29% for GBP 3600 mg. Study 2 shows 14% for placebo and 32% and 34% for GBP 1800 mg and 2400 mg, respectively. Statistical significance is indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)

A scatter plot chart comparing percentage difference values against daily dose in mg for Gabapentin studies labeled as Study a, Study b, and Study c. The x-axis shows daily dose ranging from 600 mg to 1800 mg, and the y-axis shows difference percentages from 2% to 22%. Data points are marked with different symbols representing each study.*

FDA Label Image

Chemical Structure (Gabapentin Str)

Chemical structure diagram of gabapentin showing a cyclohexane ring with attached amino (CH2NH2) and carboxymethyl (CH2CO2H) groups.*

FDA Label Image

Label Image (Lbl500900949)

Label for Gabapentin 100 mg capsules by A-S Medication Solutions. The label states each capsule contains 100 mg of gabapentin USP. It includes storage instructions to store at 68 to 77 degrees Fahrenheit and indicates a package count of 30 capsules. The label also lists the NDC 50090-0949-0 and the product number 5734-0.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.